GlassScriptPhysician profile
Surexa S Cacodcar
NPI 1104826684
$2,495.04
in general payments reported to CMS, 2019-2025
19 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $179 · 2021: $54.52 · 2022: $630 · 2023: $558 · 2024: $446 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $857.31 | 2019-2024 | Xarelto |
| Abbott Laboratories | $293.46 | 2022-2024 | Aveir, Mitraclip |
| Pfizer INC. | $234.18 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $205.76 | 2019-2025 | |
| Boston Scientific Corporation | $159.08 | 2020-2023 | Watchman Flx |
| Edwards Lifesciences Corporation | $135.40 | 2019-2025 | Sapien 3 Ultra Resilia |
| Impulse Dynamics (USA) INC. | $132.24 | 2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.64 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $85.10 | 2021-2025 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $52.95 | 2019-2023 | Camzyos |
| Daiichi Sankyo INC. | $43.25 | 2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $42.77 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $29.33 | 2023 | Inpefa |
| Amgen INC. | $27.86 | 2019-2020 | |
| Philips North America LLC | $25.02 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.45 | 2024 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $20.55 | 2024 | |
| Astellas Pharma US INC | $19.14 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.55 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surexa Cacodcar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.